Email Alert | RSS

Chinese Journal of Antituberculosis ›› 2025, Vol. 47 ›› Issue (5): 666-672.doi: 10.19982/j.issn.1000-6621.20240523

• Review Articles • Previous Articles     Next Articles

Research progress on CRISPR/Cas molecular diagnosis of drug-resistant Mycobacterium tuberculosis

Wang Yuanning1, Du Zongmin2()   

  1. 1School of Public Health, Mudanjiang Medical University, Mudanjiang 157011, China
    2State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China
  • Received:2024-11-22 Online:2025-05-10 Published:2025-04-29
  • Contact: Du Zongmin E-mail:zmduams@163.com

Abstract:

Tuberculosis (TB) remains a significant global public health challenge. China is a high-burden country of TB and also a country with high burden of multidrug-resistant and rifampin-resistant TB. The development of rapid and sensitive methods for detecting the drug resistance of Mycobacterium tuberculosis is of great significance for the control and treatment of TB. Clustered regularly interspaced short palindromic repeats (CRISPR) as a component bacterial adaptive immunity can efficiently and specifically recognize and cleave exogenous nucleic acid targets. Meanwhile, some CRISPR-associated proteins (Cas) have trans-cleavage activity, paving the way for novel applications in CRISPR/Cas-based diagnostics for TB drug resistance. Therefore, this review summarizes the latest advancements in CRISPR/Cas technologies for detection Mycobacterium tuberculosis and its drug resistance, and discusses the future trends in this field.

Key words: Mycobacterium tuberculosis, Tuberculosis, multidrug-resistant, Diagnose technology, Molecular diagnostic techniques, Review

CLC Number: